Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.

Background: Standard therapy to prevent recurrent venous thromboembolism includes 3 to 12 months of treatment with full-dose warfarin with a target international normalized ratio (INR) between 2.0 and 3.0.